



6-28-04

JFW

AM-101251

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Appln. No. : 10/810,517 Confirmation No.: 1212
Applicant : Kreft et al.
Filed : March 26, 2004
TC/A.U. : 1626
Examiner : unassigned
Customer No. : 38199
Title : FLUORO- AND TRIFLUOROALKYL-CONTAINING
HETEROCYCLIC SULFONAMIDE INHIBITORS OF BETA-
AMYLOID PRODUCTION AND DERIVATIVES THEREOF

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:

Applicants submit to the Examiner the attached Form PTO/SB/08A/B document listing and this paper pursuant to 37 CFR § 1.56 and § 1.97-1.98. Form PTO/SB/08A/B is attached and copies of the documents are enclosed herewith. This Information Disclosure Statement is submitted less than three months from the filing date of this application and before the receipt of a first Office Action on the merits. Therefore, no fees are believed due.

The Director is hereby authorized to charge any deficiency in any fees due with the filing of this paper or credit any overpayment in any fees to our Deposit Account Number 08-3040.

Express Mail No. EU531571505US


REMARKS

Listed below are previously filed, and co-pending, US Patent applications.

- (i) US Provisional Patent Application No. 60/255,105, filed December 13, 2000 (now abandoned)
- (ii) US Patent Application No. 10/014,304, filed December 11, 2001, now US Patent No. 6,610,734, issued August 26, 2003 (item BC)
International Patent Application No. PCT/US01/48375, published as International Patent Publication No. WO 02/057252 on July 25, 2002 (item CP)
- (iii) US Patent Application No. 10/166,896, filed June 11, 2002, now US Patent No. 6,657,070, issued December 2, 2003 (item BB)
International Patent Application No. PCT/US02/38117, published as International Patent Publication No. WO 03/050062 on June 19, 2003 (item DM)
- (iv) US Patent Application No. 10/455,674, filed June 5, 2003
(US Patent Publication No. US-20030229127-A1, published December 11, 2003 (item BD))
- (v) US Provisional Patent Application No. 60/387,690, filed June 11, 2002 (now abandoned)
- (vi) US Patent Application No. 10/457,641, filed June 9, 2003
(US Patent Publication No. US-20040006050-A1, published January 8, 2004 (item BF))
International Patent Application No. PCT/US03/18198, published as International Patent Publication No. WO 03/103660-A1 on December 18, 2003 (item DL)
- (vii) US Provisional Patent Application No. 60/339,264, filed December 11, 2001 (now abandoned)
- (viii) US Patent Application No. 10/304,322, filed November 26, 2003
(US Patent Publication No. 20030144531-A1, published July 31, 2003 (item BE))
International Patent Application No. PCT/US02/38119, published as International Patent Publication No. WO 03/050063 on June 19, 2003 (item CQ)

An English translation of document BO was not available. Applicants have therefore provided a copy of an English language abstract as document DL and the following remarks:

This document describes sulfonamide derivatives of the following structure (I):



where: R^1 = lower alkyl, aryl, aralkyl, heteroaryl, heteroarylalkyl (all optionally substituted), COR^6 , or $-\text{NHCO}-(\text{CH}_2)_x-\text{R}^{26}$;

R^2 = H, lower alkyl, $-(\text{CH}_2)_t-\text{O}-\text{R}^{27}$ or aralkyl

R^3 = optionally substituted arylene or heteroarylene, or a single bond;

R^4 = $-(\text{CH}_2)_n-$, $-\text{CH}=\text{CH}-$, $-\text{C}\equiv\text{C}-$, $-\text{CO}-$, $-\text{CO}-\text{NH}-$, $-\text{N}=\text{N}-$, $-(\text{R}')-$, $-\text{NH}-\text{CO}-\text{NH}-$, $-\text{NH}-\text{CO}-$, $-\text{O}-$, $-\text{S}-$, $-\text{SO}_2\text{NH}-$, $-\text{SO}_2-\text{NH}-\text{N}=\text{CH}-$, tetrazolediyl, piperazinediyl, piperidinediyl, or a single bond;


R^5 = optionally substituted aryl, optionally substituted heteroaryl, optionally substituted alkyl, aralkyl, aralkyloxy, non-aromatic heterocyclic, or lower alkyloxycarbonyl (lower alkenyl);

X = $-\text{SR}^7$, $-\text{OR}^8$, $-\text{SCOR}^9$, $-\text{OCOR}^{10}$, $-\text{XCO}^2\text{R}^{25}$, or $-\text{SCONHR}^{11}$; and


m = 1 or 2;

wherein R^1 is not CH_3 or aminocarbonyl when R^3 and R^4 are single bonds and R^5 is optionally substituted aryl or heteroaryl.

This document also describes the following specific compounds (II) and (III):



(II)



(III)

The compounds of item BO are assertedly useful as $\text{TNF-}\alpha$ inhibitors, treating autoimmune diseases such as chronic rheumatism, Crohn's disease, myasthenia gravis, systemic lupus erythematosus, asthma, diabetes type I, and psoriasis.

The months of publication for documents AR-AT, AX, BU-BW, CS, CV, and CY-CZ could not be determined. The years of publication for documents AR-AT, AZ, BU-BW, CS, and CY-CZ are sufficiently earlier than the effective US filing date and/or the foreign priority date of the present application so that the particular months of publication of these documents is not in issue (MPEP 609).


The Examiner is respectfully requested to consider the enclosed documents identified in this paper and in the attached Form PTO/SB/08A/B during the course of examination of this application.

The Director is hereby authorized to charge any deficiency in any fees due with the filing of this paper or credit any overpayment in any fees to our Deposit Account Number 08-3040.

Respectfully submitted,

HOWSON AND HOWSON
Attorneys for Applicants

By Cathy A. Kdroff
Cathy A. Kdroff
Registration No. 33,980
Spring House Corporate Center
Box 457
Spring House, PA 19477
Telephone: (215) 540-9200
Telefacsimile: (215) 540-5818



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

**TRANSMITTAL
FORM**

(to be used for all correspondence after initial filing)

Application Number	10/810,517	
	Filing Date	March 26, 2004
	First Named Inventor	Kreft et al.
	Art Unit	1626
	Examiner Name	unassigned
Attorney Docket Number	AM-101251	
Total Number of Pages in This Submission	11	

ENCLOSURES (Check all that apply)

<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input type="checkbox"/> Amendment/Reply <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input checked="" type="checkbox"/> Information Disclosure Statement <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Response to Missing Parts/ Incomplete Application <input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s) _____	<input type="checkbox"/> After Allowance communication to Technology Center (TC) <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input type="checkbox"/> Other Enclosure(s) (please Identify below):
Remarks Customer No. 38199 Express Mail No. EU531571505US		

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm or Individual name	HOWSON AND HOWSON Cathy A. Kodroff
Signature	
Date	June 25, 2004

CERTIFICATE OF TRANSMISSION/MAILING

I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below.

Typed or printed name			
Signature		Date	

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



PTO/SB/08A (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/810,517
				Filing Date	March 26, 2004
				First Named Inventor	Kreft et al.
				Group Art Unit	1626
				Examiner Name	unassigned
Sheet	1	of	6	Attorney Docket Number	AM-101251

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
	AA	US-5,981,168	P. Reiner	11-09-1999	
	AB	US-5,624,937	J. Reel	04-29-1997	
	AC	US-5,703,129	K. Felsenstein	12-30-1997	
	AD	US-5,593,846	D. Schenk	01-14-1997	
	AE	US-5,852,007	S. Chatterjee	12-22-1998	
	AF	US-6,248,775	Vasquez	06-19-2001	
	AG	US-6,376,523	Chan, et al.	04-23-2002	
	AH	US-5,594,021	Chan, et al.	01-14-1997	Claims 1 and 2, and Specification

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ - Number ⁴ -Kind Code ⁵ (if known)				
	AL	WO-95/29904-A1	11-09-1995	K. Chow		
	AM	WO-98/03166-A1	01-29-1998	G. DeCrescenzo		
	AN	WO-98/22104-A3	05-28-1998	G. Pasinetti		
	AO	WO-98/22493-A2	05-28-1998	J. Audia		
	AP	WO-00/09107-A2	02-24-2000	D. Ross		
	AQ	WO-00/50391-A1	08-31-2000	D. Smith		

Examiner Signature	Date Considered
--------------------	-----------------

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of Information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 USC 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETE FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/810,517
				Filing Date	March 26, 2004
				First Named Inventor	Kreft et al.
				Group Art Unit	1626
				Examiner Name	unassigned
Sheet	2	of	6	Attorney Docket Number	AM-101251

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
	AI	US-5,571,821	Chan, et al.	11-05-1996	
	AJ	US-5,464,853	Chan, et al.	01-07-1997	
	AK	US-5,591,761	Chan, et al.	05-07-1996	
	BA	US-5,514,691	Chan, et al.	11-07-1995	

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ - Number ⁴ -Kind Code ⁵ (if known)				
	BL	EP-652,009	05-10-1995	V. John		
	BM	EP-510,700-A2	10-28-1992	K. Itoh et al.		
	BN	EP-1,172,361-A1	12-14-1999	Watanabe et al.		
	BO	JP-5-148233	06-15-1993	Y. Ito		√
	BP	JP-11-343279	01-16-2002	F. Watanabe		
	BQ	WO-01/27091-A1	04-19-2001	Thompson		
	CL	WO-01/27108-A1	04-19-2001	Thompson		
	CM	WO-01/23379-A1	04-05-2001	Arkinstall et al.		
	CN	EP-1,088,821-A1	04-04-2001	Arkinstall		

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 USC 122 and 37 CFR 1.14. this collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETE FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/810,517
				Filing Date	March 26, 2004
				First Named Inventor	Kreft et al.
				Group Art Unit	1626
				Examiner Name	unassigned
Sheet	3	of	6	Attorney Docket Number	AM-101251

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
	BB	US-6,657,070	12-02-2003	Resnick, et al.	
	BC	US-6,610,734	08-26-2003	Kreft, et al.	
	BD	US-20030229127-A1	12-11-2003	Kreft, et al.	
	BE	US-20030144531-A1	07-31-2003	Kreft, et al.	
	BF	US-20040006050-A1	01-08-2004	Kreft, et al.	
	BG	6,566,536	05-20-2003	Muller, et al.	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ - Number ⁴ -Kind Code ⁵ (if known)				
	CO	WO-01/70677-A1	09-27-2001	Belanger et al.		
	CP	WO-02/057252-A1	07-25-2002	Kreft et al.		
	CQ	WO-03/050063-A1	06-19-2003	Kreft et al.		
	DL	WO-03/103660-A1	12-18-2003	Kreft et al.		
	DM	WO-03/050062-A1	06-19-2003	Resnick et al.		

Examiner Signature	Date Considered
--------------------	-----------------

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 USC 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETE FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/810,517
				Filing Date	March 26, 2004
				First Named Inventor	Kreft et al.
				Group Art Unit	1626
				Examiner Name	unassigned
Sheet	4	of	6	Attorney Docket Number	AM-101251

NONPATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include the name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item, (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
	AR	A. LARNER et al, "Review - Central & Peripheral Nervous Systems - Alzheimer's Disease: Towards Therapeutic Manipulation of the Amyloid Precursor Protein and Amyloid β -peptides", Exp. Opin. Ther. Patents, 7(10):1115-1127 (1997)	
	AS	C. MOORE et al, "Inhibition of β -amyloid Formation as a Therapeutic Strategy", Exp. Opin. Ther. Patents, 9(2):135-146 (1999)	
	AT	V. JOHN et al, "Alzheimer's Disease: Recent Advances on the Amyloid Hypothesis", in Annual Reports in Medicinal Chemistry, Chapter 2, pp. 11-20 (1997)	
	AU	G. RISHTON et al, "Fenchylamine Sulfonamide Inhibitors of Amyloid β Peptide Production by the γ -Secretase Proteolytic Pathway: Potential Small-Molecule Therapeutic Agents for the Treatment of Alzheimer's Disease", J. Med. Chem., 43(12):2297-2299 (June 15, 2000)	
	AV	B. TESTA et al, "Prodrugs Revisited: The "Ad Hoc" Approach as a Complement to Ligand Design", Medicinal Research Reviews, 16(3):233-241 (May, 1996)	
	AW	D. SKOVRONSKY et al, " β -Secretase Revealed: Starting Gate for Race to Novel Therapies for Alzheimer's Disease", TIPS, 21:161-163 (May, 2000)	
	AX	A. GHOSH et al, "Design of Potent Inhibitors for Human Brain Memapsin 2 (β -Secretase)", J. Am. Chem. Soc., 122:3522-3523 (2000)	
	AY	W. ESLER et al, "Transition-State Analogue Inhibitors of γ -Secretase Bind Directly to Presenilin-1", Nature Cell Biology, 2:428-434 (July, 2000)	
	AZ	Y-M. LI et al, "Photoactivated γ -Secretase Inhibitors Directed to the Active Site Covalently Label Presenilin 1", Nature, 405:689-694 (June, 2000)	
	BR	M. WOLFE et al, "A Substrate-Based Difluoro Ketone Selectively Inhibits Alzheimer's β -Secretase Activity", J. Med. Chem., 41:6-9 (January 1, 1998)	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 USC 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETE FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/810,517
				Filing Date	March 26, 2004
				First Named Inventor	Kreft et al.
				Group Art Unit	1626
				Examiner Name	unassigned
Sheet	5	of	6	Attorney Docket Number	AM-101251

NONPATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include the name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item, (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
	BS	S. SINHA et al, "Purification and Cloning of Amyloid Precursor Protein β -Secretase from Human Brain", Nature, 402:537-540 (December, 1999)	
	BT	A. GOATE, "Monogenetic Determinants of Alzheimer's Disease: APP Mutations", CMLS Cell. Mol. Life Sci., 54:897-901 (September, 1998)	
	BU	M. SABBAGH et al, " β -Amyloid and Treatment Opportunities for Alzheimer's Disease", Alzheimer's Disease Review, 3:1-19 (1997)	
	BV	C. AUGELLI-SZAFRAN et al, " β -Amyloid as a Target for Alzheimer's Disease Therapy, in Annual Reports in Medicinal Chemistry, Chapter 3, pp. 21-30 (1999)	
	BW	J-C. DODART et al, "The β -Amyloid Precursor Protein and its Derivatives: from Biology to Learning and Memory Processes", Reviews in the Neurosciences, 11(2-3):75-93 (2000)	
	BX	D. SMALL et al, "Alzheimer's Disease and the Amyloid β Protein: What is the Role of Amyloid?", Journal of Neurochemistry, 73(2):443-449 (August, 1999)	
	BY	J. NÄSLUND et al, "Correlation Between Elevated Levels of Amyloid β -Peptide in the Brain and Cognitive Decline", JAMA, 283(12):1571-1577 (March, 2000)	
	BZ	Q-X. LI et al, "The Amyloid Precursor Protein of Alzheimer Disease in Human Brain and Blood", Journal of Leukocyte Biology, 66:567-574 (October, 1999)	
	CR	S. WAGNER et al, "Modulation of Amyloid β Protein Precursor Processing as a Means of Retarding Progression of Alzheimer's Disease", The Journal of Clinical Investigation, 104(10):1329-1332 (November, 1999)	
	CS	Y. HAN et al, "Total Asymmetric Synthesis of Highly Constrained Amino Acids Isopropyl-2', 6'-Dimethyl-Tyrosines", Tetrahedron Letters, 38(29):5135-5138 (1997)	
	CT	M. FINDEIS et al, "Modified-Peptide Inhibitors of Amyloid β -Peptide Polymerization", Biochemistry, 38(21):6791-6800 (May, 1999)	

Examiner Signature	Date Considered
-----------------------	--------------------

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 USC 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETE FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/810,517
				Filing Date	March 26, 2004
				First Named Inventor	Kreft et al.
				Group Art Unit	1626
				Examiner Name	unassigned
Sheet	6	of	6	Attorney Docket Number	AM-101251

NONPATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include the name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item, (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
	CU	ROGGO, "Inhibition of BACE, A Promising Approach to Alzheimer's Disease Therapy", Curr. Top. Med. Chem., 2(4): 359-70 (April 2002)	
	CV	TUNG et al., "Design of Substrate-Based Inhibitors of Human β -Secretase", J. Med. Chem., 45(2):259-262 (2002)	
	CW	JOSIEN, "Recent Advances in the Development of Gamma-Secretase Inhibitors", Curr. Opin. Drug. Discov. Devel., 5(4):513-25 (July 2002)	
	CX	DOVEY et al., "Functional Gamma-Secretase Inhibitors Reduce Beta-Amyloid Peptide Levels in Brain", J. Neurochem., 76:173-181 (January 2001)	
	CY	OLSON et al., "Chapter 4. Secretase Inhibitors as Therapeutics for Alzheimer's Disease", Ann. Reports in Med. Chem., 35:31 (2000)	
	CZ	VARGHESE et al., "Chapter 2. Alzheimer's Disease: Recent Advances on the Amyloid Hypothesis", Ann. Reports Med. Chem., 32:11 (1997)	
	DL	Abstract of Japanese Patent No. JP-11-343279, January 26, 2002	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.
¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.
 This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 USC 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETE FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.